Mutational spectra at the hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus in T-lymphocytes of nonsmoking and smoking lung cancer patients

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 468, Issue 1, 2000, Pages 45-61

  Hackman, Peter ^a   Hou, Sai Mei ^a   Nyberg, Fredrik ^a   Pershagen, Göran ^a   Lambert, Bo ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Hypoxanthine guanine phosphoribosyltransferase (HPRT) gene; Lung cancer; Mutational spectra; Smoking; Somatic gene mutation; T lymphocytes

Indexed keywords

BENZO[A]PYRENE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE INSERTION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; DNA, COMPLEMENTARY; FEMALE; FRAMESHIFT MUTATION; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POINT MUTATION; SEQUENCE DELETION; SMOKING; T-LYMPHOCYTES;

NICOTIANA TABACUM;

EID: 0034702373     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(00)00039-5     Document Type: Article

References (54)

1. Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in relation to smoking: 40 years observations on male British doctors. Br. Med. J. 309:1994;901-911.
2. Wynder E., Hoffman D. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res. 54:1994;5284-5295.
3. Vineis P., Caporaso N. Tobacco and cancer: epidemiology and the laboratory. Environ. Health Perspect. 103:1995;156-160.
4. Hoffman D., Hoffman I. Significance of exposure to sidestream tobacco smoke. O'Neill I.K., Brunneman K.D., Dodet B., Hoffman D. Environmental Carcinogens: Methods of Analysis and Exposure Measurement. Passive Smoking. Vol. 9:1987;3-10 IARC Scientific Publication No. 81, Lyon, France.
5. Dockery D.W., Trichopoulus D. Risk of lung cancer from environmental exposures to tobacco smoke. Cancer Causes Control. 8:1997;333-345.
6. Hackshaw A.K., Law M.R., Wald N.J. The accumulated evidence on lung cancer and environmental tobacco smoke. Br. Med. J. 315:1997;961-962.
7. Phillips D.H., Hewer A., Martin C., Garner R.C., King M.M. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature (London). 336:1988;790-792.
8. Tang D., Santella M.R., Blackwood A.M., Young T.L., Mayer J., Jaretzki A., Grantham S., Tsai W.T., Perera F. A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol. Biomarkers Prev. 4:1995;341-346.
9. Brownon R., Alavanja M., Caporaso N., Simoes E., Chang J. Epidemiology and prevention of lung cancer in nonsmokers. Epidemiol. Rev. 20:1998;218-236.
10. Lubin J., Boice J. Jr. Lung cancer risk from residential radon: meta-analysis of eight epidemiological studies. J. Natl. Cancer Inst. 89:1997;49-57.
11. Ziegler R.G., Mayne S.T., Swanson C.A. Nutrition and lung cancer. Cancer Causes Control. 7:1996;157-177.
12. Steenland K., Loomis D., Shy C., Simonsen N. Review of occupational lung carcinogens. Am. J. Ind. Med. 29:1996;474-490.
13. Strauss B. The origin of point mutations in human tumor cells. Cancer Res. 52:1992;249-253.
14. Vogelstein B., Kinzler K. The multistep nature of cancer. Trends Genet. 9:1993;138-141.
15. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
16. Hernandez-Boussard T., Hainaut P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ. Health Perspect. 106:1998;385-391.
17. Albertini R.J., Nicklas J.A., Fuscoe J.C., Skopek T.R., Branda R.F., O'Neill J.P. In vivo mutations in human blood cells: biomarkers for molecular epidemiology. Environ. Health Perspect. 99:1993;135-141.
18. Albertini R.J. Why use somatic mutations for human biomonitoring? Environ. Mol. Mutagen. 23(Suppl. 24):1994;18-22.
19. Albertini R.J., Nicklas J.A., O'Neill J.P., Robison S.H. In vivo somatic mutations in humans: measurement and analysis. Annu. Rev. Genet. 24:1990;305-326.
20. Cariello N.F., Skopek T.R. Analysis of mutations occurring at the human hprt locus. J. Mol. Biol. 231:1993;41-57.
21. Cole J., Skopek T. Somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo. Mutat. Res. 304:1994;33-106.
22. Kat A.G., Thilly W. Mutational spectra of endogenous genes in mammalian cells. Hemminki K., Dipple A., Shuker D.E.G., Kadlubar F.F., Segerbäck D., Bartsch H. DNA Adducts: Identification and Biological Significance. 1994;371-383 IARC Scientific Publications No. 125, Lyon, France.
23. Cariello N.F. Software for the analysis of mutations at the human hprt gene. Mutat. Res. 312:1994;173-185. Release 6 of the human HPRT mutation database, Mutabase Software Durham, NC, August 1996.
24. Robinson D.R., Goodall K., Albertini R., O'Neill P., Finette B., Sala-Trepat M., Moustachi E., Tates A., Beare D., Green M., Cole J. An analysis of in vivo hprt mutant frequency in circulating T-lymphocytes in the normal human population: a comparison of four datasets. Mutat. Res. 313:1994;227-247.
25. Hou S.M., Yang K., Nyberg F., Hemminki K., Pershagen G., Lambert B. Hprt mutant frequency and aromatic DNA adduct level in nonsmoking lung cancer patients and population controls. Carcinogenesis (London). 20:1999;437-444.
26. Jones I., Moore D.H., Thomas C.B., Thompson C.L., Strout C., Burkhart-Schultz K. Factors affecting HPRT mutant frequency in T-lymphocytes of smokers and nonsmokers. Cancer Epidemiol. Biomarkers Prev. 2:1993;249-260.
27. Karnaoukhova L., Moffat J., Martins H., Glickman B. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy. Cancer Res. 57:1997;4393-4407.
28. Sawada M., Kubota M., Lin Y.-W., Watanabe K.I., Koishi S., Usami I., Akiyama Y., Matsumura T., Furusho K. Prospective study of mutant frequencies at the hprt and T-cell receptor gene loci in pediatric cancer patients during chemotherapy. Cancer Epidemiol. Biomarkers Prev. 7:1998;711-717.
29. Tates A.D., van Dam F.J., Natarajan A.T., Zwinderman A.H., Osanto S. Frequencies of HPRT mutants and micronuclei in lymphocytes of cancer patients under chemotherapy: a prospective study. Mutat. Res. 307:1994;293-306.
30. Podlutsky A., Hou S.M., Nyberg F., Pershagen G., Lambert B. Influence of smoking and donor age on the spectrum of in vivo mutation at the hprt locus in T-lymphocytes of healthy adults. Mutat. Res. 431:1999;325-339.
31. Burkhart-Schultz K.J., Thompson C.L., Jones I.M. Spectrum of somatic mutations at the hypoxanthine phosphoribosyltransferase (hprt) gene of healthy people. Carcinogenesis (London). 17:1996;1871-1883.
32. Burkhart-Schultz K.J., Jones I.M. Deletion and insertion in vivo somatic mutations in the hypoxanthine phosporibosyl transferase (hprt) gene of human T-lymphocytes. Environ. Mol. Mutagen. 30:1997;371-384.
33. Podlutsky A., Österholm A.-M., Hou S.-M., Hofmaier A., Lambert B. Spectrum of point mutations in the coding region of the hypoxanthine-guanine phosphoribosyltransferase (hprt) gene in human T-lymphocytes in vivo. Carcinogenesis (London). 19:1998;557-566.
34. Nyberg F., Hou S.-M., Hemminki K., Lambert B., Pershagen G. GSTM1 and NAT2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls. Cancer Epidemiol. Biomarkers Prev. 7:1998;875-883.
35. F. Nyberg, Environmental and genetic factors in lung cancer epidemiological and biomolecular studies focusing on nonsmokers, Doctoral Thesis, The Karolinska Institute, Stockholm, 1998.
36. Albertini R.J., Castle K.L., Borcherding W.R. T-cell cloning to detect the mutant 6-thioguanine-resistant lymphocytes present in human peripheral blood. Proc. Natl. Acad. Sci. U. S. A. 79:1982;6617-6621.
37. Österholm A.-M., Fält S., Lambert B., Hou S.-M. Classification of mutations at the human hprt locus in T-lymphocytes of bus maintenance workers by multiplex PCR and reverse transcriptase PCR analysis. Carcinogenesis (London). 16:1995;1909-1912.
38. Österholm A.-M., Hou S.-M. Splicing mutations at the HPRT locus in human T-lymphocytes in vivo. Environ. Mol. Mutagen. 32:1998;1-10.
39. Adams W.T., Skopek T.R. Statistical test for the comparison of samples from mutational spectra. J. Mol. Biol. 194:1987;391-396.
40. O'Neill J.P., Finette B.A. Transition mutations at CpG dinucleotides are the most frequent in vivo spontaneous single base mutation in the human HPRT gene. Environ. Mol. Mutagen. 32:1998;188-191.
41. Albertini A.M., Hofer M., Calos M., Miller J. On the formation of spontaneous deletions: the importance of short sequence homologies in the generation of large deletions. Cell. 29:1982;319-328.
42. Streisinger G., Okada Y., Emrich J., Newton J., Tsugita A., Terzaghi E., Inouye M. Frameshift mutations and the genetic code. Cold Spring Harbor Symp. Quant. Biol. 31:1966;77-84.
43. Glickman B., Ripley L. Structural intermediates of deletion mutagenesis: a role for palindromic DNA. Proc. Natl. Acad. Sci. U. S. A. 81:1984;512-516.
44. Ripley L.S. Model for the participation of quasi-palindromic DNA sequences in frameshift mutation. Proc. Natl. Acad. Sci. U. S. A. 79:1982;4128-4132.
45. Österholm A.-M., Hou S.-M., Lambert B. Sequence analysis of deletion mutations at the HPRT locus of human T-lymphocytes: association of a palindromic structure with a breakpoint cluster in exon 2. Mutagenesis. 11:1996;511-517.
46. O'Neill J.P., Rogan P., Cariello N., Nicklas J.A. Mutations that alter RNA splicing of the human HPRT gene: a review of the spectrum. Mutat. Res. 411:1998;179-214.
47. O'Neill J.P., Nicklas J.A., Hunter T.C., Batson O.B., Allegretta M., Falta M.T., Branda R.F., Albertini R.J. The effect of T-lymphocyte clonality on the calculated human hprt mutation frequency occurring in vivo in humans. Mutat. Res. 313:1994;215-225.
48. Vrieling H., Thijssen J.C.P., Rossi A.-M., van Dam F.J., Natarajan A.T., Tates A.D., van Zeeland A.A. Enhanced hprt mutant frequency but no significant difference in mutation spectrum between smoking and a nonsmoking human population. Carcinogenesis (London). 13:1992;1625-1631.
49. Andersson B., Fält S., Lambert B. Strand specificity for mutations induced by (+)-anti-BPDE in the hprt gene in human T-lymphocytes. Mutat. Res. 269:1992;129-140.
50. Chen R.H., Maher V., McCormick J. Effect of excision repair by diploid human fibroblasts on the kinds and locations of mutations induced by (±)-7β,8α-dihydroxy-9α, 10α-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene in the coding region of the HPRT gene. Proc. Natl. Acad. Sci. U. S. A. 87:1990;8680-8684.
51. Denissenko M.F., Pao A., Tang M.-S., Pfeifer G.P. Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in p53. Science. 274:1996;430-432.
52. Eisenstadt E., Warren A., Porter J., Atkins D., Miller J. Carcinogenic epoxides of benzo(a)pyrene- and cyclopenta(c,d)pyrene-induced base substitutions via specific transversions. Proc. Natl. Acad. Sci. U. S. A. 79:1982;1945-1949.
53. Greenblatt M., Grollman A., Harris C. Deletions and insertions in the p53 gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res. 56:1996;2130-2136.
54. Hollstein M., Moeckel G., Hergenhahn M., Spiegelhalder B., Keil M., Werle-Shneider G., Bartsch H., Brickmann J. On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat. Res. 405:1998;145-154.